CA2899746A1 - Composition pharmaceutique contenant du leflunomide - Google Patents

Composition pharmaceutique contenant du leflunomide Download PDF

Info

Publication number
CA2899746A1
CA2899746A1 CA2899746A CA2899746A CA2899746A1 CA 2899746 A1 CA2899746 A1 CA 2899746A1 CA 2899746 A CA2899746 A CA 2899746A CA 2899746 A CA2899746 A CA 2899746A CA 2899746 A1 CA2899746 A1 CA 2899746A1
Authority
CA
Canada
Prior art keywords
leflunomide
pharmaceutical composition
arthritis
eur
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2899746A
Other languages
English (en)
Inventor
Jens Flemming
Harm Peters
Andreas Brandt
Heiner Will
Marguerite M. Mensonides-Harsema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Medac Gesellschaft fuer Klinische Spezialpraeparate mbH
Alfred E Tiefenbacher GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201310001636 external-priority patent/DE102013001636A1/de
Priority claimed from DE102013007106.2A external-priority patent/DE102013007106A1/de
Application filed by Medac Gesellschaft fuer Klinische Spezialpraeparate mbH, Alfred E Tiefenbacher GmbH and Co KG filed Critical Medac Gesellschaft fuer Klinische Spezialpraeparate mbH
Publication of CA2899746A1 publication Critical patent/CA2899746A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique contenant 14 à 17,5 mg de léflunomide, préparée sous forme de dose unitaire, ainsi que ses utilisations.
CA2899746A 2013-01-31 2014-01-06 Composition pharmaceutique contenant du leflunomide Abandoned CA2899746A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102013001636.3 2013-01-31
DE201310001636 DE102013001636A1 (de) 2013-01-31 2013-01-31 Pharmazeutische Zusammensetzung umfassend Leflunomid
DE102013007106.2A DE102013007106A1 (de) 2013-04-25 2013-04-25 Pharmazeutische Zusammensetzung umfassend Leflunomid
DE102013007106.2 2013-04-25
PCT/EP2014/000006 WO2014096464A1 (fr) 2013-01-31 2014-01-06 Composition pharmaceutique contenant du léflunomide

Publications (1)

Publication Number Publication Date
CA2899746A1 true CA2899746A1 (fr) 2014-06-26

Family

ID=49955310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2899746A Abandoned CA2899746A1 (fr) 2013-01-31 2014-01-06 Composition pharmaceutique contenant du leflunomide

Country Status (3)

Country Link
EP (1) EP2950796A1 (fr)
CA (1) CA2899746A1 (fr)
WO (1) WO2014096464A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105287420A (zh) * 2015-12-03 2016-02-03 李正梅 一种治疗成人类风湿性关节炎的来氟米特片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法

Also Published As

Publication number Publication date
EP2950796A1 (fr) 2015-12-09
WO2014096464A1 (fr) 2014-06-26

Similar Documents

Publication Publication Date Title
RU2769132C2 (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
TWI732785B (zh) 雜環化合物及其用途
EP2282779B1 (fr) Nouvelles approches thérapeutiques pour traiter la maladie d'alzheimer et les troubles qui lui sont associés par modulation de la réponse au stress cellulaire
Kumar et al. Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type
CN104870998B (zh) 对作为TOR激酶抑制活性标记的PRAS40、GSK3‑β或P70S6K1的磷酸化抑制
ES2959842T3 (es) Combinación de un agonista de PPAR con un agonista de FXR
US20120282187A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
US7067261B2 (en) Methods and compositions for treatment of central nervous system disorders
TW201932109A (zh) 治療肝臟疾病之方法
CN105377299B (zh) 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
US20120277269A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
CN107137402A (zh) 用tor激酶抑制剂治疗癌症
CN107667092A (zh) 作为fgfr4抑制剂的甲酰化n‑杂环衍生物
TW201605454A (zh) 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
JP2011525194A (ja) 線維性疾患または病態を治療するための組成物
UA126977C2 (uk) Таблетка деферипрону з відтермінованим вивільненням та спосіб її виготовлення
Lorrio et al. Novel multitarget ligand ITH33/IQM9. 21 provides neuroprotection in in vitro and in vivo models related to brain ischemia
TW201120042A (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
Wang et al. ANKRD22 is a novel therapeutic target for gastric mucosal injury
US20140045898A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
CN106794180A (zh) 联合疗法
Zhang et al. Pretreatment with metformin prevents microcystin‐LR‐induced tau hyperphosphorylation via mTOR‐dependent PP2A and GSK‐3β activation
JP2003531174A (ja) Ｐｄｅ５インヒビターを使用する勃起機能不全に対する毎日の処置
JP2021504462A (ja) トロポミオシン受容体キナーゼａ（ｔｒｋａ）阻害剤としてのピリミジン誘導体
CA2899746A1 (fr) Composition pharmaceutique contenant du leflunomide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181219

FZDE Discontinued

Effective date: 20220706

FZDE Discontinued

Effective date: 20220706